Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2019; 55(03): 138-144
DOI: 10.1055/s-0039-3399406
Review Article
National Academy of Medical Sciences (India)

Cancer Therapy: A Brief Outline

Smita Kayal
1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, Puducherry, India
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2019 (online)

   Permissions and Reprints

Abstract

Modern cancer treatment has evolved over several years to reach the current era of precision therapy. Exciting developments in all modalities of cancer treatment and rapidly growing arena of translational research are contributing to the steady improvement in clinical outcomes. Although several old and new challenges have to be overcome, parallel technological advances in the tools and techniques of drug discovery has promise for future. An outline of the overall approach to cancer management and a broad perspective of multimodality treatment methods are discussed in this brief review.

Keywords

cancer - treatment - review
 

  • References

  • 1 DeVita Jr VT. Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012; 366 (23) 2207-2214
    CrossrefPubMedGoogle Scholar
  • 2 Arruebo M, Vilaboa N, Sáez-Gutierrez B. et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel) 2011; 3 (03) 3279-3330
    CrossrefPubMedGoogle Scholar
  • 3 Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther 2009; 1 (02) 1-4
    CrossrefPubMedGoogle Scholar
  • 4 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 5 Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009; 69 (02) 383-392
    CrossrefPubMedGoogle Scholar
  • 6 Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 2017; 11 (Suppl. 05) 87
    CrossrefPubMedGoogle Scholar
  • 7 Fisher B. Biological research in the evolution of cancer surgery: a personal perspective. Cancer Res 2008; 68 (24) 10007-10020
    CrossrefPubMedGoogle Scholar
  • 8 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks [Internet]. Available at: https://www.nccn.org/evidenceblocks/default.aspx Accessed September 18, 2019
  • 9 Oncology Clinical Practice Guidelines | ESMO [Internet]. Available at: https://www.esmo.org/Guidelines. Accessed September 18, 2019
  • 10 Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J 2017; 20 (01) 4
    PubMedGoogle Scholar
  • 11 Concetta Crisafulli C, Romeo PD, Calabrò M, Epasto LM, Alberti S. Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resist 2019; 2: 225-241
    Google Scholar
  • 12 Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011; 194 (02) 73-77
    CrossrefPubMedGoogle Scholar
  • 13 Tralongo P, Maso LD, Surbone A. et al. Use of the word “cured” for cancer patients—implications for patients and physicians: the Siracusa charter. Curr Oncol 2015; 22 (01) e38-e40
    CrossrefGoogle Scholar
  • 14 Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther 2016; 38 (07) 1551-1566
    CrossrefPubMedGoogle Scholar
  • 15 Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 2018; 9: 1300
    CrossrefPubMedGoogle Scholar